Investors like AZ, AbbVie merger idea; Beleaguered Forest CEO sees bright future;

 @FiercePharma: Daiichi to take over ‪Ranbaxy‬ unit's marketing in Venezuela, latest "hybrid business model" move to make buyout pay off. More | Follow @FiercePharma

> Shares of U.K. drugmaker AstraZeneca ($AZN) jumped Tuesday after a Liberum Capital analyst suggested that it would be the perfect merger partner for Abbott's ($ABT) planned spinoff AbbVie. Story

> Ranbaxy Laboratories, which is operating under an extensive consent decree with U.S. regulators, has been given a four-day suspension from authorities in India for "flouting" rules for storing products. Story

> India used the BIO 2012 conference to release new "similar biologics" guidelines that will require manufacturers of biosimilars to prove similarity within four years of postmarket safety data to either a drug licensed in India or one approved elsewhere. Story

> Ranbaxy Laboratories, which had used a local distributor to market its drugs in Venezuela, is turning that responsibility over to Daiichi Sankyo. Item

> On the same day that news broke that the FDA user fee reauthorization bill would not contain provisions for a track-and-trace program, the FDA announced that it intended to continue a proof-of-concept program for securing the drugmaking supply chain. Story

> CDMO AMRI ($AMRI) CFO Mark Frost says the company is looking to further cut operations in the U.S. as it braces for patent losses that will hurt its revenue. Story

Biotech News

 @FierceBiotech: Check out our live coverage of ‪BIO 2012‬ in Boston. More | Follow @FierceBiotech

 @JohnCFierce: Tesaro sets IPO terms, looks to raise about $81M, with $25M maybe coming from insiders - I'd like to see this one work. More | Follow @JohnCFierce

 @RyanMFierce: Thanks @Millennium_US, Shire, and Biogen for participating on our ‪BIO 2012‬ panel. We drew a crowd and covered a lot. | Follow @RyanMFierce

> Investors offer grim odds of success for two big Alzheimer's programs. Story

> Tesaro insiders pledge support for $86M IPO gamble. Article

> Biotech employment, salaries weather a stormy economic downturn. News

Medical Devices News 

 @FierceMedDev: We have extended the nomination deadline for the 15 fiercest medical device developers to July 13. Spread the word. Survey | Follow @FierceMedDev

> Exclusive: Allegro Diagnostics is raising a $15M-$20M Series B round. Story

> Expect steady growth for the urological devices market. More

> Bard pours $40M-plus into Puerto Rican device production expansion. News

Drug Delivery News

 @DamianFierce: Drugmakers are rethinking drug delivery methods for multiple sclerosis treatments. Report | Follow @DamianFierce

> Notre Dame's nanoparticles effective against drug-resistant cancer. Story

> Ambrx nabs $303M deal with Merck for 'smart bomb' delivery. Article

> TheStreet: Alkermes should stick to drug delivery. More

> Explosive nanocarriers thwart target cells' defenses. News

Biomarkers News

> Blood test for pancreatic cancer may be possible. Story

> Huntington's disease marker emerges in clinical trial. News

> Biodesix feels the buzz at BIO2012. Article

And Finally... Forest ($FRX) CEO Howard Solomon, whose company faces a proxy fight with Carl Icahn and the loss of patents on its best-selling drug, Lexapro, told financial analysts Wednesday that the company's future looks good. Story